Kelonia data advance the durability narrative around in vivo CAR Ts at ASCO

The spotless clinical track record of Kelonia that led to its $7 billion acquisition by Eli Lilly announced in April continues through this year’s ASCO. The company reported that all 18 patients now treated with the in vivo CAR T achieved an objective response, and the six patients with at least four months of follow-up remain free of measurable residual disease.

The updated results from the first-in-human trial bring the in vivo CAR T modality one step closer to validation of its durability of effect, and represent one of the many examples of headline data emerging from this year’s American Society of Clinical Oncology (ASCO) meeting...